reMYND

Gaston Geenslaan 1
3001 Leuven
BE
reMYND
Foundation date
07/02/2002
Sector
#Biotechnology - TherapeuticsSubsector
- #Therapeutics - Small molecules
- #R&D Services - CRO (Contract Research Organization)
- #R&D Services - Screening
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the nervous system
- #Endocrine - nutritional and metabolic diseases
reMYND actively drives the development of disease modifying treatments against Alzheimer’s disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation (CRO) or through its own drug discovery & development (DDD).
Upcoming events
All events-
1212 '23
BioFIT 2023
Event by: Eurasanté -
0602 '24
Discovery to Innovation in Animal Health - 2024
Event by: Ghent University, Provaxs, Paul Dick & Associates -
0712 '23
The GxP Academy: Cleaning Validatie
Event by: Advipro
Latest news
More news-
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China
1 day ago
Read more
-
Celyad announces management change
Friday December 1st 2023
Read more
-
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
Thursday November 30th 2023
Read more
Jobs by reMYND
More jobsMore info?
Ellen Telleir
Communication Coordinator